Glaukos Corp.

Glaukos Corp. is a global ophthalmic medical device and pharmaceutical company focused on developing and commercializing novel therapies for chronic eye diseases. The company operates three primary therapeutic areas: Glaucoma (market-leading innovative therapy portfolio), Cornea (cross-linking interventions for keratoconus), and Retina (sustained-release drug delivery platforms for retinal diseases). Glaukos has achieved FDA approval for Epioxa and maintains a robust pipeline of novel ophthalmic treatments. The company reinvests approximately 30% of sales into research and development activities. As a B2B partner, Glaukos provides comprehensive clinical support, physician educational resources, training modules, and patient education materials to help ophthalmology practices integrate their products and therapies. The company serves ophthalmologists and surgical centers specializing in glaucoma management, corneal disease treatment, and retinal therapeutics. Glaukos is committed to advancing the standard of care in ophthalmology through continuous innovation and clinical evidence generation.